Wegovy vs Ozempic side effects in 2026: complete comparison

Why the side-effect profile looks similar

Wegovy and Ozempic both contain semaglutide manufactured by Novo Nordisk. Same molecule, same mechanism, same biological pathway. The side-effect categories are therefore essentially identical: GI (nausea, vomiting, diarrhea, constipation), fatigue, headache, and rare serious effects (pancreatitis, gallbladder issues, thyroid cancer warning).

The reported rates differ across the two trial programs because Wegovy was tested at higher doses (up to 2.4mg weekly) and in patients without diabetes, while Ozempic was tested at lower doses (up to 2.0mg) in patients with T2D. Higher dose + non-diabetic population = generally more pronounced GI side effects in the Wegovy trials.

Most common GI side effects head-to-head

Nausea: Wegovy 44% (STEP-1) vs Ozempic 20% (SUSTAIN-6). Peak during titration, settles at maintenance dose for most patients within 4-12 weeks.

Diarrhea: Wegovy 30% vs Ozempic 9%. More common at higher doses; usually mild and self-limiting.

Vomiting: Wegovy 24% vs Ozempic 9%. Often correlates with dose escalation; tends to settle once dose is stable.

Constipation: Wegovy 24% vs Ozempic 5%. Often the more persistent side effect — many patients deal with it long-term, not just during titration.

Abdominal pain: Wegovy 20% vs Ozempic 7%. Usually upper abdominal; severe or persistent pain warrants pancreatitis workup.

Side effects that don't follow the dose pattern

Sulfur burps. Affects 20-40% of GLP-1 patients across both drugs. Caused by slowed gastric emptying + sulfur-reducing bacteria fermentation. Same on Wegovy and Ozempic — dose doesn't change frequency much.

Fatigue. Reported at ~10-15% across both drugs. Often most pronounced early in treatment and after dose increases. Settles within weeks usually.

Hair loss. Reported at 3% Wegovy vs 1.4% placebo in STEP-1. The mechanism is telogen effluvium from rapid weight loss (not direct drug effect). Resolves within 6-9 months of weight stabilization.

Gallbladder issues. Cholelithiasis risk increased on both drugs — about 1.6% in STEP-1 vs 0.7% placebo. Rapid weight loss is the primary driver, not the drug per se.

Serious side effects — same warnings, same actual rates

Pancreatitis. Boxed warning on both labels. Actual rate ~0.3% per year in real-world data. Symptoms: severe upper abdominal pain radiating to back, often with nausea/vomiting. Call your prescriber immediately if you experience these.

Thyroid cancer (medullary). Boxed warning derived from rodent studies. No confirmed causal human cases in 15+ years of GLP-1 use. Personal or family history of MTC or MEN2 is an absolute contraindication for both drugs.

Acute kidney injury. Risk elevated during severe vomiting/diarrhea (volume depletion). Both drugs equally affected. Pause dose if you can't keep liquids down for 24+ hours.

Diabetic retinopathy worsening. SUSTAIN trial signal in patients with pre-existing T2D retinopathy. Relevant for Ozempic patients specifically; less of a concern for Wegovy patients without T2D.

Management strategies (same for both)

Slow titration. If side effects are severe, your prescriber can extend each dose level (8 weeks instead of 4) or skip a dose level entirely. This reduces side-effect intensity at the cost of slower symptom buildup.

Dietary adjustments. Smaller, more frequent meals. Protein first. Avoid fried/high-fat/sulfur-rich foods during titration. See our foods-to-avoid article for full guide.

Anti-nausea medication. Ondansetron (Zofran) on hand for the 24-48 hours after weekly injection. Many prescribers write a small Rx pre-emptively.

Hydration. 2-3L daily, more during peak side-effect periods. Adequate hydration directly reduces nausea severity.

Bowel regimen for constipation. Adequate fiber (psyllium), magnesium citrate at night, hydration. Many patients need ongoing bowel support, not just episodic.

When to switch from one to the other

Wegovy → Ozempic switch (for tolerability): if you're on Wegovy and side effects are intolerable even at lower doses, switching to Ozempic at a comparable dose may help (same molecule, but Ozempic typically stops at 2.0mg vs 2.4mg). Insurance coverage may be the gate — Ozempic requires T2D indication for coverage.

Ozempic → Wegovy switch (for efficacy): if you're on Ozempic for weight loss off-label and want the higher dose ceiling, switching to Wegovy unlocks 2.4mg dose. Expect somewhat more pronounced side effects at the higher dose.

Cross-class switch (semaglutide → tirzepatide): if side effects of semaglutide (either Wegovy or Ozempic) are intolerable, switching to tirzepatide (Mounjaro or Zepbound) may help — different molecule, somewhat different side-effect profile. About 30% of semaglutide-intolerant patients tolerate tirzepatide better.